Ambiq Micro (AMBQ) Q2 2025 earnings summary

Executive summary

• Q2 2025 net sales were $17.9M, up 13.6% sequentially but down year-over-year, reflecting a strategic shift away from China and strong demand for edge AI solutions.

• Gross margin improved to 40.1%–42.7% from 31.7%–32.9% year-over-year, driven by favorable product and customer mix.

• Completed IPO in July 2025, raising $97.2M in net proceeds to support growth, R&D, and IP licensing initiatives.

• Sales to Mainland China dropped to 11.5%–12% of Q2 2025 net sales, down from 42% in Q2 2024, as focus shifted to higher-value markets.

• Received Frost & Sullivan's 2025 Global Company of the Year Award for leadership in healthcare semiconductor solutions.

Financial highlights

• Q2 2025 net sales: $17.9M (up from $15.7M in Q1, down from $20.3M YoY); six-month net sales: $33.6M (down 5.2% YoY).

• Gross profit: $7.2M–$7.6M (40.1%–42.7% margin), up from $6.4M–$6.7M (31.7%–32.9%) YoY.

• Net loss: $8.5M (GAAP), improved from $10.6M YoY; non-GAAP net loss: $5.9M, improved from $7.4M YoY.

• Cash and equivalents: $47.5M at Q2 end, with $97.2M raised post-quarter from IPO.

• Operating cash flow deficit for six months ended June 30, 2025: $10.5M.

Outlook and guidance

• Q3 2025 net sales expected between $17.5M and $18.0M.

• Non-GAAP loss per share projected between $0.35 and $0.28, with share count baseline at 18.2M.

• Gross margin expected to remain around 43%, with minor fluctuations based on product mix.

• Management expects continued margin improvement as sales shift away from Mainland China.

• Cautiously optimistic for H2 2025, with tariff impacts expected to be less severe.